Quantcast
Newark, DE
55°
Weather from OpenWeatherMap
Tuesday, November 12, 2019

Microsoft tablet computer aimed at taking on IPad – Bloomberg

Microsoft Corp. unveiled its own Windows-powered tablet computer called Surface, altering its strategy of focusing on software and relying on partners to make the machines in a renewed attempt to take on the Apple...

Newark-based iBio makes progress on patent

The U.S. Patent Office has accepted a patent application for the iBio Inc. iBioModulator platform. The platform aims to improve the potency and effectiveness of vaccines used to fight flu, anthrax and other diseases...

AstraZeneca among pharma companies seeking antibiotics answers

   A growing worry in medicine is bugs’ increasing resistance to antibiotics. At AstraZeneca’s research centre near Boston, scientists toil to find new weapons. Machines screen thousands of drugs each year, robotic arms nimbly handling...

DuPont opens new office building

DuPont last week opened a new five-story, 220,000 square foot office building at its Chestnut Run facility – incorporating sustainability into the building design and using more than 20 DuPont innovations. The building is...

SDIX reports loss, partnership with drug company

 SDIX, a Glasgow, Del. provider of biotechnology-based products and services reported a loss for the quarter and a partnership with a drug company. Revenue for the first quarter of 2012 was $5.6 million, down...

DuPont acquires remainder of soy venture

DuPont,  on May 1,  took  full ownership of St. Louis-based soy-based ingredients  joint venture  Solae. DuPont previously owned 72 percent  of the joint venture while grain merchant  Bunge owned the  remainder. Published reports indicate...

WEEK IN REVIEW – A tale of 2 pharma companies, casino earnings perk up

Most businesspeople in Delaware know little about Incyte. The pharmaceutical development company, based in DuPont research space at the Experimental Station has quietly built a portfolio of promising drugs while posting big losses. Earlier in the...

Incyte posts loss as stock price stays around 52-week high

Drug developer Incyte Corp. is reporting revenue from a new product on the market, although the company's loss widened in the first quarter, due to higher research and other expenses as its pharmaceuticals moved...

AstraZeneca $1.26 paying billion for developer of gout drug

  AstraZeneca headquarters in London. AstraZeneca is betting on the success of a promising drug used to treat gout in  its merger deal for Ardea Biosciences, Inc. AstraZeneca will acquire Ardea, a San Diego-based biotechnology company...

AstraZeneca, Bristol-Myers Squibb drug wins OK from European panel

AstraZeneca and Bristol-Myers Squibb Company reported a committee for a European Union agency has recommended the approval of FORXIGA tablets for the treatment of type 2 diabetes. The drug is used in additon to diet...